Early Access — free while we kick the tires
EdgarHawk

EITAN YARON

Director

Director
2 filings analyzed · 1 company · Latest 2025-11-12

Companies

Company Buys Sells Direction
Marpai, Inc. MRAI 3 0 Net buying

Activity

November 2025
2025-11-12 Marpai, Inc. MRAI
medium
Buy
100,000 shares
$100,000
Significance 5/10

Director Eitan Yaron buys 100,000 shares of MRAI at $1.00; stock down -27.4% from 52-week high amid -24.2% annual revenue decline.

Director Eitan Yaron purchased 100,000 shares at $1.00 on 2025-11-07, increasing his holdings by 10.1% to 1,089,073 shares post-transaction. The purchase occurs against a deteriorating stock backdrop: MRAI is trading -27.4% from its 52-week high and -9.8% over the last 30 days, while fundamentals show annual revenue declining -24.2% and the company posting a full-year net loss of $-3,494,000.00. His prior five buys at MRAI show mixed timing: two achieved positive 90-day returns (including a +122.8% gain following a January 2024 purchase), but three resulted in 90-day losses of -20.4%, -24.8%, and -46.7%, suggesting inconsistent execution. The filing also reflects a cluster pattern with 2 other insiders buying within the past 14 days, which may indicate coordinated confidence or response to external circumstances rather than isolated conviction.

December 2024
2024-12-09 Marpai, Inc. MRAI
medium
Buy
110,619 shares
$124,999
Significance 6/10

Director Eitan Yaron buys 110.6K MRAI shares at $1.13; stakes cluster buy, follows 52-week recovery +63.1% (30d), +112.4% (90d)

Eitan Yaron purchased 110,619 shares at $1.13 on 2024-12-05, increasing his holdings by 16.3% to 789,073 shares total. This purchase occurs alongside 2 other insider buys within the past 14 days, forming a cluster pattern. The timing coincides with significant recent price momentum—the stock has rallied +63.1% over 30 days and +112.4% over 90 days from near its 52-week low of $0.43, though it remains -54.8% below its 52-week high of $2.81. At the same ticker, Yaron's prior 4 purchases show mixed outcomes: 2 were followed by positive 90-day returns (+122.8%, +34.5%), while 2 saw declines (-77.4%, -46.7%), suggesting inconsistent timing at MRAI. The company remains unprofitable with a net loss of $3,560,000 in the latest quarter against $7,008,000 in quarterly revenue, though full-year revenue growth reached +52.6% year-over-year. The concurrent multi-insider buying activity warrants attention to whether this reflects information known to management or simply a reaction to the steep recent recovery.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access